Suppr超能文献

基于呋咱并吡嗪的新型有前景抗癌药物,通过双重抑制微粒体前列腺素E合酶-1(mPGES-1)和可溶性环氧化物水解酶(sEH)干扰类花生酸生物合成途径。

Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition.

作者信息

Lauro Gianluigi, Aliberti Michela, De Nisco Mauro, Pedatella Silvana, Pepe Giacomo, Basilicata Manuela Giovanna, Chini Maria Giovanna, Fischer Katrin, Hofstetter Robert K, Werz Oliver, Ferraro Maria Grazia, Piccolo Marialuisa, Irace Carlo, Saviano Anella, Campiglia Pietro, Bertamino Alessia, Ostacolo Carmine, Ciaglia Tania, Manfra Michele, Bifulco Giuseppe

机构信息

Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, Fisciano, 84084, Italy.

Department of Health Sciences, University of Basilicata, Viale dell'Ateneo Lucano, Potenza, I-85100, Italy.

出版信息

Eur J Med Chem. 2025 May 5;289:117402. doi: 10.1016/j.ejmech.2025.117402. Epub 2025 Feb 18.

Abstract

We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group. A focused virtual library of 1 × 10 molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 and, among them, two items featured IC values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound 3b, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for 3b; on the other hand, compound 7e exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether moiety possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of 7e and 7d, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells. These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.

摘要

我们报告了一组基于呋咱并吡嗪核心的新化合物的鉴定结果,这些化合物可干扰类花生酸生物合成,并作为潜在有效的抗炎和抗癌药物。基于我们之前在一组基于呋咱并吡嗪的化合物对微粒体前列腺素E合酶-1(mPGES-1)酶的研究中取得的有希望的结果,我们在此通过用更稳定的醚基取代酯部分,鉴定出了具有改善药代动力学性质的衍生物。构建了一个包含1×10个分子的聚焦虚拟文库,并通过分子对接实验针对mPGES-1进行筛选,从而选择了10个用于合成和生物学评价的候选物。发现几种分子可抑制mPGES-1,其中有两种的IC值在低微摩尔范围内。对合成化合物集合的进一步计算研究表明,先前作为mPGES-1抑制剂出现的化合物3b干扰可溶性环氧化物水解酶(sEH)的活性,因此成为一种有价值的双重mPGES-1/sEH抑制剂。对最有效的化合物的药代动力学特征进行了准确评估。不幸的是,3b的结果不佳;另一方面,化合物7e表现出有希望的mPGES-1抑制作用和出色的药代动力学特征,表明与我们先前研究中报道的基于酯的化合物相比,新型含醚基的基于呋咱并吡嗪的化合物具有改善的药代动力学性质。此外,评估了7e和7d(后者是最具活性的mPGES-1抑制剂)的抗癌特性,两种化合物对HCT-116人结肠直肠癌(CRC)细胞均显示出有希望的活性。这些发现突出了呋咱并吡嗪核心作为一种有前途的支架,可用于开发能够抑制花生四烯酸级联反应中靶点的新型抗炎药物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验